Articles

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study

CNRS UMR 5235, University of Montpellier, France;Department of Clinical Hematology, University Hospital Montpellier, France
INSERM, U1183, Institute of Regenerative Medicine and Biotherapy, University Hospital Montpellier, France
Henri Becquerel Center, Rouen, France
Department of Clinical Hematology, Hospital Center of Annecy, Pringy, France
Department of Biological Hematology, APHP, GHUPSSD, Avicenne Hospital, Bobigny, France
Department of Clinical Hematology, Pontchaillou Hospital, Rennes, France
Department of Bacteriology-Virology, University Hospital Montpellier, France
Department of Hematology, La Pitié Salpétrière Hospital, Paris, France
INSERM, U1183, Institute of Regenerative Medicine and Biotherapy, University Hospital Montpellier, France
CNRS UMR 7292, François Rabelais University, University Hospital Tours, France
Department of Hematology, Cote Basque Hospital, Bayonne, France
Department of Clinical Hematology, University Hospital Estaing, Clermont-Ferrand, France
Unit of Lymphoid Hematologic Malignancies, Henri Mondor Hospital, Créteil, France
INSERM, U1183, Institute of Regenerative Medicine and Biotherapy, University Hospital Montpellier, France;Clinical department for Osteoarticular Diseases, University Hospital Lapeyronie, Montpellier, France
CNRS UMR 5235, University of Montpellier, France;Department of Clinical Hematology, University Hospital Montpellier, France
INSERM, U1183, Institute of Regenerative Medicine and Biotherapy, University Hospital Montpellier, France;Clinical department for Osteoarticular Diseases, University Hospital Lapeyronie, Montpellier, France
Vol. 102 No. 4 (2017): April, 2017 https://doi.org/10.3324/haematol.2016.153189